Zulresso™ (Brexanolone)

Policy Number: CS2020D0080E
Effective Date: December 1, 2020

Table of Contents
Application ..................................................................................... 1
Coverage Rationale ....................................................................... 1
Applicable Codes .......................................................................... 2
Background.................................................................................... 2
Clinical Evidence ........................................................................... 2
U.S. Food and Drug Administration ............................................. 2
Centers for Medicare and Medicaid Services ............................. 3
References ..................................................................................... 3
Policy History/Revision Information ............................................. 3
Instructions for Use ....................................................................... 3

Application

This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

<table>
<thead>
<tr>
<th>State</th>
<th>Policy/Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kansas</td>
<td>None</td>
</tr>
<tr>
<td>Kentucky</td>
<td>Zulresso™ (Brexanolone) (for Kentucky Only)</td>
</tr>
<tr>
<td>Louisiana</td>
<td>Refer to the state’s Medicaid clinical policy</td>
</tr>
</tbody>
</table>

Coverage Rationale

Brexanolone is proven for the treatment of postpartum depression.

Brexanolone is medically necessary for the treatment of postpartum depression in patients who meet all of the following criteria:

- Diagnosis of major depressive disorder (MDD) according to the current DSM (i.e., DSM-5), by a mental health professional; and
- Onset of current depressive episode was during the third trimester and 4 weeks postpartum; and
- Current depressive episode is considered moderate to severe based on a standardized, validated tool; and
- Patient has not previously received brexanolone for the current postpartum depressive episode from the most recent pregnancy (within 6 months); and
- The provider and/or the provider’s healthcare setting is certified in the Zulresso REMS program, with ability to support onsite continuous monitoring; and
- Brexanolone is dosed in accordance with the United States Food and Drug Administration approved labeling; and
- Approval is for a single 60 hour infusion

Commercial Policy

- Zulresso™ (Brexanolone)
Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1632</td>
<td>Injection, brexanolone, 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F53.0</td>
<td>Postpartum depression</td>
</tr>
</tbody>
</table>

Background

Brexanolone is a neuroactive steroid GABA A receptor positive modulator, that is chemically identical to endogenous allopregnanolone.

Clinical Evidence

Meltzer-Brody et al assessed brexanolone as a treatment for moderate to severe postpartum depression (PPD) in two double-blind, randomised, placebo-controlled, phase 3 trials. Women in the trial were 18-45 years of age, 6 months post partum or less at screening, and diagnosed with PPD with a Hamilton Rating Scale for Depression (HAM-D) score of ≥26 and 20-25 for study 1 and study 2, respectively. Study participants were randomly assigned to receive either brexanolone 90 μg/kg per hr (BRX90), brexanolone 60 μg/kg per hr (BRX60), or matching placebo for a single 60 hour infusion in study 1. In study 2 BRX90 or placebo was infused as a single 60 hour infusion. The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 hours. This was assessed in all patients who started infusion of brexanolone or placebo, had a valid HAM-D baseline assessment, and had at least one post-baseline HAM-D assessment. The trials are NCT02942004 (study 1) and NCT02942017 (study 2). In study 1, at 60 hours, the least-squares (LS) mean reduction in HAM-D total score from baseline was 19.5 points (SE 1.2) in the BRX60 group and 17.7 points (1.2) in the BRX90 group compared with 14.0 points (1.1) in the placebo group (difference -5.5 [95% CI -8.8 to -2.2], p=0.0013 for the BRX60 group; -3.7 [95% CI -6.9 to -0.5], p=0.0252 for the BRX90 group). In study 2, at 60 hours, the LS mean reduction in HAM-D total score from baseline was 14.6 points (SE 0.8) in the BRX90 group compared with 12.1 points (SE 0.8) for the placebo group (difference -2.5 [95% CI -4.5 to -0.5], p=0·0160). The authors conclude that brexanolone for PPD resulted in significant and clinically meaningful reductions in HAM-D total score at 60 hours compared with placebo, with rapid onset of action and durable treatment response during the study period. The authors conclude that results suggest that brexanolone injection is a novel therapeutic drug for PPD that has the potential to improve treatment options for women with this disorder.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Zulresso is indicated for the treatment of postpartum depression (PPD) in adults.

Zulresso is only available through a restricted program under a REMS called the Zulresso REMS due to the risk of excessive sedation or sudden loss of consciousness that can result in serious harm.

Important requirements of the Zulresso REMS include the following:

- Healthcare facilities must enroll in the program and ensure that Zulresso is only administered to patients who are enrolled in the Zulresso REMS
Pharmacies must be certified with the program and must only dispense Zulresso to healthcare facilities who are certified in the Zulresso REMS
- Patients must be enrolled in the Zulresso REMS prior to administration of Zulresso
- Wholesalers and distributors must be registered with the program and must only distribute to certified healthcare facilities and pharmacies

Centers for Medicare and Medicaid Services (CMS)

Medicare does not have a National Coverage Determination (NCD) for Zulresso™ (brexanolone) CIV. Local Coverage Determinations (LCDs) do not exist. (Accessed June 22, 2020)

References


Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
</table>
| 02/01/2021       | Application
                  - Reformatted content
                  - Added language to indicate this policy does not apply to the state of Kentucky; refer to the state-specific policy version |
| 12/01/2020       | Application
                  - Removed reference link to the Medical Benefit Drug Policy titled Zulresso™ (Brexanolone) (for Louisiana Only) (retired Dec. 1, 2020)
                  - Added instruction to refer to the state’s Medicaid clinical policy
                  - Supporting Information
                  - Archived previous policy version CS2020D0080D |

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with
the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.